Vi­a­tris agrees to pay $264M to set­tle EpiPen class ac­tion case

Just as Bio­con signs off on a $3.3 bil­lion buy­out of their shared biosim­i­lars busi­ness, Vi­a­tris’s pend­ing law­suit for its con­tro­ver­sial EpiPen might be no more — if the court signs off on it.

Keep­ing de­tails short, the phar­ma snuck in an an­nounce­ment about its EpiPen prod­uct in its Q4 re­port:

The Com­pa­ny has agreed, sub­ject to ap­proval by the Court, to a $264 mil­lion set­tle­ment, while deny­ing any al­le­ga­tion of wrong­do­ing, to re­solve the EpiPen Au­to-In­jec­tor in­di­rect pur­chas­er class ac­tion cas­es pend­ing in the U.S. Dis­trict Court for the Dis­trict of Kansas.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER